Research programme: vancomycin nanoparticles - AlphaRx

Drug Profile

Research programme: vancomycin nanoparticles - AlphaRx

Alternative Names: Vancomycin nanoparticles; Vansolin

Latest Information Update: 23 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AlphaRx
  • Class Glycopeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Nosocomial pneumonia; Sepsis

Most Recent Events

  • 18 Feb 2010 Preclinical development is ongoing
  • 27 May 2008 AlphaRx establishes CRADA with US Army for the development of antibacterial nanoparticles in severe intracellular bacterial infections
  • 12 Nov 2007 Preclinical data added to the pharmacokinetics and Bacterial Infections pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top